Business
Nov 23, 2025 · tact.cgkik.top

Bayer reports positive results for blood thinner after 2023 setback

BERLIN (Reuters) -German pharma company Bayer reported positive study ​results for its anticoagulant asundexian on Sunday,‌ two years after a research setback for the ‌promising blood thinner candidate.

In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared ⁠with a placebo,‌ Bayer said.

Detailed results from the OCEANIC-STROKE study will be presented ‍at an upcoming scientific congress, said Bayer.

Bayer added that it plans to speak with health ​authorities worldwide in preparation for the submission ‌of marketing authorisation applications.

Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any ⁠of its other drugs.

At ​the end of 2023,​ the company had a major setback with the drug after it failed ‍in a ⁠pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.

($1 ⁠= 0.8687 euros)

(Reporting by Joern Poltz.‌ Writing by Miranda Murray. ‌Editing by Jane Merriman)

You Might Also Like

News

Little Italy Mercato brings fresh food and community to downtown San Diego

News

Dancing through the crackdown: The satirical song soundtracking post-Khamenei Iran

News

'Not the moon that I'm used to seeing': Artemis II astronauts describe seeing the far side

News

Canada's Friendly Sunshine Coast City Is An Outdoor Playground Perfect For Hiking And Paddling